Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Petros Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/15/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment to the Amended and Restated By-laws of Petros Pharmaceuticals, Inc."
08/15/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/21/2023 D Form D - Notice of Exempt Offering of Securities:
07/13/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "CERTIFICATE OF DESIGNATIONS OF CONVERTIBLE PREFERRED STOCK OF",
"Form of Warrant Neither the issuance and sale of the securities represented by this certificate nor the securities into which these securities are exercisable have been registered under the securities act of 1933, as amended, or applicable state securities laws. The securities may not be offered for sale, sold, transferred or assigned in the absence of an effective registration statement for the securities under the securities act of 1933, as amended, or an opinion of counsel to the holder , in a form reasonably acceptable to the company, that registration is not required under said act or unless sold or eligible to be sold pursuant to rule 144 or rule 144a under said act. Notwithstanding the foregoing, the securities may be pledged in connection with a bona fide margin account or other lo...",
"RECITALS",
"Registration Rights Agreement",
"Petros Pharmaceuticals Announces Capital Raise of $15 million"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 4 Bradley Greg (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.
Txns: Exercised 6,050 restricted stock units @ $0
04/28/2023 4 Bernstein Bruce (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.
Txns: Exercised 6,050 restricted stock units @ $0
04/28/2023 4 WALKER WAYNE REMELL (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.
Txns: Exercised 6,050 restricted stock units @ $0
04/28/2023 4 Silverman Joshua (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.
Txns: Exercised 6,722 restricted stock units @ $0
03/31/2023 10-K Annual Report for the period ended December 31, 2022
02/08/2023 SC 13G/A INTRACOASTAL CAPITAL, LLC reports a 7.6% stake in Petros Pharmaceuticals, Inc.
01/25/2023 4 WALKER WAYNE REMELL (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.
Txns: Exercised 2,264 restricted stock units @ $0
01/25/2023 4 Silverman Joshua (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.
Txns: Exercised 2,515 restricted stock units @ $0
01/25/2023 4 Bradley Greg (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.
Txns: Exercised 2,264 restricted stock units @ $0
01/25/2023 4 Bernstein Bruce (Director) has filed a Form 4 on Petros Pharmaceuticals, Inc.
Txns: Exercised 2,264 restricted stock units @ $0
11/30/2022 8-K Quarterly results
11/15/2022 8-K Quarterly results
Docs: "Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update"
11/14/2022 10-Q/A Quarterly Report for the period ended September 30, 2022 [amend]
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/21/2022 EFFECT Form EFFECT - Notice of Effectiveness:
10/14/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
10/12/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/12/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
09/30/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/15/2022 8-K Quarterly results
Docs: "Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022"
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Petros Pharmaceuticals Responds to Fraudulent Press Release"
06/24/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy